文献速递白血病

诱导治疗时可测量残留病灶重新定义急性髓系白血病部分缓解并分层无NPM1突变标危患者结局

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
PubMed 文献 · J Clin Oncol · 2018-03-30

在NCRI AML17试验中,2450例年轻急性髓系白血病或高危骨髓增生异常综合征患者接受多参数流式细胞术可测量残留病灶(MFC-MRD)评估。第一疗程后部分缓解与MRD+生存相似,MRD+与部分缓解可归为同等不良应答;第二疗程MRD状态可独立分层,NPM1野生型标危患者中MRD+≥0.1%复发率达89%,移植获益更明显。

要点

  • 第一疗程后部分缓解与MRD+的5年总生存相似(46% vs 51%),均显著差于MRD-的70%。
  • 第二疗程MRD状态独立预测复发(HR 1.88)和生存(HR 1.77),不受第一疗程应答影响。
  • NPM1野生型标危患者第二疗程MRD+者总生存33% vs MRD- 63%,MRD+≥0.1%复发率89%。

核心结论

  • MFC-MRD可通过扩展第一疗程后部分缓解的定义来改善结局分层,并可能有助于预测可从首次完全缓解期移植中获益的NPM1野生型标危不良结局患者。

研究设计与样本

  • NCRI AML17试验的一部分,纳入2450例年轻成人急性髓系白血病或高危骨髓增生异常综合征患者,前瞻性进行多参数流式细胞术MRD(MFC-MRD)评估。
  • 第一疗程后按临床标准分为耐药病、部分缓解和完全缓解或血细胞计数未完全恢复的完全缓解(CRi),CR/CRi再按MFC-MRD分为MRD+和MRD-。
  • 无高危因素患者(包括Flt3内部串联重复野生型/NPM1野生型亚组)接受第二疗程柔红霉素/阿糖胞苷诱导,高危因素患者第二疗程强化。

主要发现

  • 第一疗程后部分缓解与MRD+的生存结局相似,尤其良好至标危亚组:5年总生存耐药病27% vs 部分缓解46% vs MRD+ 51% vs MRD- 70%,P < .001。
  • 校正分析证实第一疗程耐药病 vs 部分缓解/MRD+之间总生存差异显著,但部分缓解 vs MRD+之间无显著差异。
  • 第一疗程后CRi降低MRD+患者总生存(CRi 19% vs CR 45%,P = .001),第二疗程后影响较小。
  • 第二疗程MFC-MRD状态的预后效应(复发:HR 1.88 [95% CI, 1.50 to 2.36],P < .001;生存:HR 1.77 [95% CI, 1.41 to 2.22],P < .001)在校正第一疗程应答后仍显著。
  • 分层分析中MRD阳性在低危患者中区分度似乎较低;NPM1野生型标危亚组第二疗程MRD+与较差结局显著相关(总生存33% vs MRD- 63%,P = .003;MRD+ ≥ 0.1%时复发率89%);移植获益在MRD+患者中更明显(HR 0.72;95% CI, 0.31 to 1.69) vs MRD-患者(HR 1.68 [95% CI, 0.75 to 3.85];交互作用P = .16)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We investigated the effect on outcome of measurable or minimal residual disease (MRD) status after each induction course to evaluate the extent of its predictive value for acute myeloid leukemia (AML) risk groups, including NPM1 wild-type (wt) standard risk, when incorporated with other induction response criteria. Methods As part of the NCRI AML17 trial, 2,450 younger adult patients with AML or high-risk myelodysplastic syndrome had prospective multiparameter flow cytometric MRD (MFC-MRD) assessment. After course 1 (C1), responses were categorized as resistant disease (RD), partial remission (PR), and complete remission (CR) or complete remission with absolute neutrophil count < 1,000/µL or thrombocytopenia < 100,000/μL (CRi) by clinicians, with CR/CRi subdivided by MFC-MRD assay into MRD+ and MRD-. Patients without high-risk factors, including Flt3 internal tandem duplication wt/- NPM1-wt subgroup, received a second daunorubicin/cytosine arabinoside induction; course 2 (C2) was intensified for patients with high-risk factors. Results Survival outcomes from PR and MRD+ responses after C1 were similar, particularly for good- to standard-risk subgroups (5-year overall survival [OS], 27% RD v 46% PR v 51% MRD+ v 70% MRD-; P < .001). Adjusted analyses confirmed significant OS differences between C1 RD versus PR/MRD+ but not PR versus MRD+. CRi after C1 reduced OS in MRD+ (19% CRi v 45% CR; P = .001) patients, with a smaller effect after C2. The prognostic effect of C2 MFC-MRD status (relapse: hazard ratio [HR], 1.88 [95% CI, 1.50 to 2.36], P < .001; survival: HR, 1.77 [95% CI, 1.41 to 2.22], P < .001) remained significant when adjusting for C1 response. MRD positivity appeared less discriminatory in poor-risk patients by stratified analyses. For the NPM1-wt standard-risk subgroup, C2 MRD+ was significantly associated with poorer outcomes (OS, 33% v 63% MRD-, P = .003; relapse incidence, 89% when MRD+ ≥ 0.1%); transplant benefit was more apparent in patients with MRD+ (HR, 0.72; 95% CI, 0.31 to 1.69) than those with MRD- (HR, 1.68 [95% CI, 0.75 to 3.85]; P = .16 for interaction). Conclusion MFC-MRD can improve outcome stratification by extending the definition of partial response after first induction and may help predict NPM1-wt standard-risk patients with poor outcome who benefit from transplant in the first CR.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Freeman SD, Hills RK, Virgo P, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol. 2018. PMID: 29601212. doi:10.1200/JCO.2017.76.3425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。